A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 Jan 2024
06 Jan 2024
Historique:
received:
18
05
2023
accepted:
12
12
2023
medline:
7
1
2024
pubmed:
7
1
2024
entrez:
6
1
2024
Statut:
epublish
Résumé
In 70 patients with KIT D816V positive systemic mastocytosis (SM) including 36 patients with advanced SM (AdvSM), we correlated the extent of reported mucosal mast cell ([m]MC) infiltration of the upper and/or lower gastrointestinal tract (UGIT, n = 63; LGIT, n = 64; both, n = 57) with symptoms and markers of MC burden/subtype. GI symptoms were reported by all patients (mean 2.1 number of symptoms). A strong mMC infiltration was identified in 24 patients (UGIT, 17/63, 27%; LGIT, 19/64, 30%). Concurrent involvement of UGIT and LGIT (n = 12) correlated with female gender (75%) and a higher symptom burden (mean 2.7) but not with MC burden or subtype. Significant differences between non-AdvSM and AdvSM were reported regarding food intolerance (54% vs. 17%), cramping (54% vs. 22%) and weight loss (0% vs. 64%). KIT D816V was identified in 54/56 (96%) available biopsies. In 46 patients, digital PCR revealed a correlation with low albumin levels (r = - 0.270, P = 0.069) and the KIT D816V VAF in peripheral blood (r = 0.317, P = 0.036) but not with the extent of mMC infiltration or markers of MC burden/subtype. Although MC mediator triggered GI symptoms have a substantial impact on the quality of life, correlation to objective disease parameters is lacking thus making its systematic assessment challenging.
Identifiants
pubmed: 38184670
doi: 10.1038/s41598-023-49749-z
pii: 10.1038/s41598-023-49749-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
702Informations de copyright
© 2024. The Author(s).
Références
Valent, P. et al. Updated diagnostic criteria and classification of mast cell disorders: A consensus proposal. Hemasphere 5(11), e646 (2021).
doi: 10.1097/HS9.0000000000000646
pubmed: 34901755
pmcid: 8659997
Valent, P., Akin, C. & Metcalfe, D. D. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129(11), 1420–1427 (2017).
doi: 10.1182/blood-2016-09-731893
pubmed: 28031180
pmcid: 5356454
Valent, P. et al. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leukemia Res. 25(7), 603–625 (2001).
doi: 10.1016/S0145-2126(01)00038-8
Arber, D. A. et al. International Consensus Classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood 140(11), 1200–1228 (2022).
doi: 10.1182/blood.2022015850
pubmed: 35767897
pmcid: 9479031
Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia 36(7), 1703–1719 (2022).
doi: 10.1038/s41375-022-01613-1
pubmed: 35732831
pmcid: 9252913
Zanotti, R. et al. Refined diagnostic criteria for bone marrow mastocytosis: A proposal of the European competence network on mastocytosis. Leukemia 36(2), 516–524 (2022).
doi: 10.1038/s41375-021-01406-y
pubmed: 34545185
Reiter, A., George, T. I. & Gotlib, J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood 135(16), 1365–1376 (2020).
doi: 10.1182/blood.2019000932
pubmed: 32106312
Pardanani, A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am. J. Hematol. 96(4), 508–525 (2021).
doi: 10.1002/ajh.26118
pubmed: 33524167
Sokol, H. et al. Gastrointestinal manifestations in mastocytosis: A study of 83 patients. J. Allergy Clin. Immunol. 132(4), 866–873 (2013).
doi: 10.1016/j.jaci.2013.05.026
pubmed: 23890756
Doyle, L. A. et al. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am. J. Surg. Pathol. 38(6), 832–843 (2014).
doi: 10.1097/PAS.0000000000000190
pubmed: 24618605
pmcid: 4086834
Kirsch, R. et al. Systemic mastocytosis involving the gastrointestinal tract: Clinicopathologic and molecular study of five cases. Mod. Pathol. 21(12), 1508–1516 (2008).
doi: 10.1038/modpathol.2008.158
pubmed: 18931652
Siegert, S. I., Diebold, J., Ludolph-Hauser, D. & Löhrs, U. Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis? Am. J. Clin. Pathol. 122(4), 560–565 (2004).
doi: 10.1309/2880LF7Q6XK3HA3Q
pubmed: 15487454
Nanagas, V. C. & Kovalszki, A. Gastrointestinal manifestations of hypereosinophilic syndromes and mast cell disorders: A comprehensive review. Clin. Rev. Allergy Immunol. 57(2), 194–212 (2019).
doi: 10.1007/s12016-018-8695-y
pubmed: 30003499
Zanelli, M. et al. Gastrointestinal mastocytosis: A potential diagnostic pitfall to be aware. Int. J. Surg. Pathol. 27(6), 643–646 (2019).
doi: 10.1177/1066896919846648
pubmed: 31046499
Schwaab, J. et al. Importance of adequate diagnostic work-up for correct diagnosis of advanced systemic mastocytosis. J. Allergy Clin. Immunol. Pract. 8(9), 3121–3127 (2020).
doi: 10.1016/j.jaip.2020.05.005
pubmed: 32422371
Jawhar, M. et al. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur. J. Clin. Investig. 46(5), 392–397 (2016).
doi: 10.1111/eci.12607
Akin, C., Arock, M. & Valent, P. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet? J. Allergy Clin. Immunol. 149(6), 1912–1918 (2022).
doi: 10.1016/j.jaci.2022.04.020
pubmed: 35487307
Valent, P. et al. Personalized management strategies in mast cell disorders: ECNM-AIM user’s guide for daily clinical practice. J. Allergy Clin. Immunol. Pract. 10(8), 1999–2012 (2022).
doi: 10.1016/j.jaip.2022.03.007
pubmed: 35342031
Lübke, J. et al. Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: A registry-based analysis. J. Clin. Oncol. 40(16), 1783–1794 (2022).
doi: 10.1200/JCO.21.01849
pubmed: 35235417
Lübke, J. et al. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia 33(5), 1195–1205 (2019).
doi: 10.1038/s41375-019-0450-8
pubmed: 30911112
pmcid: 6756065
Erben, P. et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann. Hematol. 93(1), 81–88 (2014).
doi: 10.1007/s00277-013-1964-1
pubmed: 24281161
Naumann, N. et al. Adverse prognostic impact of the KIT D816V transcriptional activity in advanced systemic mastocytosis. Int. J. Mol. Sci. 22(5), 2562 (2021).
doi: 10.3390/ijms22052562
pubmed: 33806359
pmcid: 7961551
Hoermann, G. et al. Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. J. Allergy Clin. Immunol. Pract. 10(8), 1953–1963 (2022).
doi: 10.1016/j.jaip.2022.03.001
pubmed: 35283331
Arock, M. et al. KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis. Leukemia 29(6), 1223–1232 (2015).
doi: 10.1038/leu.2015.24
pubmed: 25650093
pmcid: 4522520
Kristensen, T., Vestergaard, H., Bindslev-Jensen, C., Moller, M. B. & Broesby-Olsen, S. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am. J. Hematol. 89(5), 493–498 (2014).
doi: 10.1002/ajh.23672
pubmed: 24443360
Shivji, S., Conner, J. R. & Kirsch, R. Mast cell evaluation in gastrointestinal biopsies: Should we be counting? A critical review and practical guide for the surgical pathologist. Histopathology 82, 960 (2023).
doi: 10.1111/his.14897
pubmed: 36849791
Giannetti, M. P. et al. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis. Ann. Allergy Asthma Immunol. 126(6), 655–660 (2021).
doi: 10.1016/j.anai.2021.01.016
pubmed: 33465452